CSF-tau, CSF-Aß1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer’s disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
This study evaluated the sensitivity and specificity of the cerebrospinal fluid (CSF) levels of tau-protein, amyloid-ß-peptide 1-42 (Aß1-42), ApoE-genotype and the degree of cognitive decline as diagnostic markers for Alzheimer’s disease (AD). Data was obtained from 105 AD patients and 68 controls.
Median CSF-tau levels were increased (512 pg/ml vs. 145 pg/ml, p<0.001) and Aß1-42-levels were decreased (238.5 pg/ml vs. 310 pg/ml, p<0.001) in AD patients compared to controls. A weak correlation was found between CSF-Aß1-42 and MMSE score (r=.245). Within all subjects, a correlation of CSF-Aß1-42 (r=−.337) and CSF-tau (r=.384) with age was found. The combination of CSF-tau levels and MMSE revealed the highest sensitivity (92%) and specificity (87%).
In summary, CSF-tau was a useful biological marker to discriminate AD from normal aging, neurological and psychiatric disorders. CSF-Aß1-42 showed no additional benefit in discriminating patients from controls but might be useful for tracking the severity of the disease.
- CSF-tau, CSF-Aß1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer’s disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity
Journal of Neural Transmission
Volume 110, Issue 10 , pp 1149-1160
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Keywords: Alzheimer disease, tau-protein, amyloid-beta 1-42
- Industry Sectors
- Author Affiliations
- A1. Department of Psychiatry and Psychotherapy, Hamburg, Germany, DE
- A2. Institute for Medical Biochemistry and Molecular Biology, Department of Molecular Cell Biology, Hamburg, Germany, DE
- A3. Institute for Mathematics and Data Science in Medicine, Hamburg, Germany, DE
- A4. Department of Neurology, Hamburg, Germany, DE
- A5. Max-Planck-Unit for Structural Molecular Biology, Hamburg, Germany, DE
- A6. Institute for Human Genetics, University Hospital Hamburg-Eppendorf, Hamburg, Germany, DE